End-of-life distress — the depression, anxiety, demoralization, and existential suffering that often accompany terminal illness — is the foundation indication for psilocybin-assisted therapy in Canada. It is the indication Health Canada first authorized via Section 56(1) exemptions in August 2020 (four terminally ill Canadians, TheraPsil-supported), the indication most commonly approved through the Special Access Program since the January 2022 amendment, and the indication where the peer-reviewed evidence base is strongest. The two foundational randomized trials — Griffiths et al. 2016 at Johns Hopkins and Ross et al. 2016 at NYU — both demonstrated rapid, substantial, and sustained reductions in depression and anxiety in patients with life-threatening cancer following a single high-dose psilocybin session. Agin-Liebes et al. 2020 followed the Ross cohort for 4–5 years and found that meaningful proportions of participants maintained therapeutic response. Agrawal et al. 2024 extended the model to group therapy in cancer-related MDD with strong week-8 outcomes. In Canada, Drs. Houman Farzin and Jean-François Stephan billed Quebec RAMQ for SAP-approved psilocybin-assisted therapy delivered to a patient with end-of-life distress in December 2022 — the first publicly funded psychedelic therapy in Canada. This article walks through the evidence, the Canadian regulatory and clinical context, and how ATMA CENA's preparation/integration model supports SAP-pathway palliative patients.

Key takeaways

End-of-life distress is the foundation Canadian SAP indication for psilocybin. The August 2020 Section 56 exemptions covered four terminally ill Canadians; the January 2022 SAP amendment continues this pathway.

Strongest evidence base in psychedelic medicine: Griffiths 2016 (N=51 cancer patients) and Ross 2016 (N=29) both demonstrated rapid, sustained antidepressant and anxiolytic effects at 6 months post-single-dose psilocybin.

Long-term follow-up: Agin-Liebes 2020 found 60–80% of the Ross cohort maintained response at 4–5 years.

Group therapy model: Agrawal 2024 (Sunstone Therapies, N=30 cancer patients with MDD) showed 80% sustained response and 50% remission at 8 weeks.

Quebec RAMQ public funding: Farzin / Stephan December 2022 — the first publicly funded psychedelic therapy in Canada.

Canadian palliative context: Roots to Thrive (Nanaimo) operates Canada's first SAP-authorized psilocybin-assisted group therapy program for end-of-life patients.

Distinct from MAID: psilocybin-assisted therapy is psychiatric/spiritual symptom support; it does not change underlying disease and is not framed as alternative to medical assistance in dying.

ATMA CENA supports preparation and integration for SAP-pathway palliative patients via coordinated care with the patient's prescribing palliative or psychiatric physician.

What is end-of-life distress?

End-of-life distress is the cluster of psychiatric and existential suffering that often accompanies terminal illness. Common components include:

Major depressive disorder — highly prevalent in palliative populations (~25–50% across various estimates) and often poorly responsive to conventional pharmacotherapy in the limited prognosis window.
Generalized anxiety including death anxiety specifically.
Demoralization syndrome — loss of meaning, hopelessness, sense of helplessness in the face of irreversible decline. Distinct from depression in some clinical frameworks; documented as poorly responsive to SSRIs.
Existential distress — grappling with mortality, legacy, unresolved relationships, spiritual meaning.

These conditions are clinically meaningful: they cause suffering, they are often resistant to standard antidepressants (which can take 4–6 weeks to act in patients with limited prognosis), and they contribute to consideration of medical assistance in dying. Psilocybin-assisted therapy emerged as a research focus precisely because conventional pharmacotherapy frequently falls short in this domain.

What the evidence shows — the strongest psilocybin evidence base

Griffiths 2016 — Johns Hopkins

Griffiths et al. 2016, Journal of Psychopharmacology — landmark double-blind RCT in 51 patients with life-threatening cancer and clinically significant depression or anxiety. Participants received either a single high-dose psilocybin session (22 or 30 mg per 70 kg) or a low-dose comparator, with crossover. Findings:

Substantial decreases in depression and anxiety (clinician-rated and self-reported measures).
Effects sustained at 6-month follow-up: approximately 80% of high-dose participants maintained clinically significant reductions.
Improvements in quality of life, sense of meaning, optimism, and acceptance of mortality.
No serious adverse events related to psilocybin.

This trial — alongside Ross 2016 — established end-of-life distress as the foundational psilocybin therapeutic indication and prompted the regulatory conversations that culminated in Health Canada's August 2020 Section 56 exemptions.

Ross 2016 — NYU

Ross et al. 2016, Journal of Psychopharmacology — companion double-blind RCT (N=29) in cancer-related anxiety and depression. Single 0.3 mg/kg psilocybin produced rapid and sustained antidepressant and anxiolytic effects, with response rates of 60–80% and improvements in demoralization, hopelessness, and spiritual wellbeing at 6.5 months.

Agin-Liebes 2020 — long-term follow-up

Agin-Liebes et al. 2020, Journal of Psychopharmacology followed up the Ross 2016 NYU cohort 4–5 years later. Of the 15 participants still alive, 60–80% maintained clinically significant antidepressant or anxiolytic responses. Participants overwhelmingly (71–100%) attributed positive life changes to psilocybin-assisted therapy and rated the experience among the most meaningful and spiritually significant of their lives. The honest framing: this is unusual durability for a single psychiatric intervention and reflects the integration of the experience into ongoing psychological adaptation to terminal illness.

Agrawal 2024 — group therapy model in cancer-related MDD

Agrawal et al. 2024, Cancer — Phase II open-label trial at Sunstone Therapies (N=30) using a single 25 mg psilocybin session paired with group therapy in cancer patients diagnosed with major depressive disorder. At week 8:

Mean MADRS reduction of 19.1 points (p<0.0001) — robust antidepressant effect.
80% sustained therapeutic response.
50% achieved full remission of depressive symptoms.
No serious adverse events.

Notably, ~50% of participants had curable (not terminal) cancer, which broadened the indication to cancer-related MDD beyond strict end-of-life. The group therapy structure also demonstrated operational efficiency for delivering psilocybin-assisted care to populations with complex medical needs.

Anderson 2020 — demoralization

Anderson et al. 2020, EClinicalMedicine — pilot psilocybin-assisted group therapy for demoralized older long-term AIDS-survivor men (N=18, mean age 59). Single dose; psilocybin-assisted group format. Findings: zero serious adverse reactions; clinically meaningful improvement in demoralization at 3-month follow-up. Demoralization is a cardinal feature of end-of-life distress and historically poorly responsive to conventional pharmacotherapy.

Mechanism evidence

The therapeutic effect at end-of-life appears to involve both the neurobiological mechanism (5-HT2A agonism, default mode network modulation, neuroplasticity) and a phenomenological component:

Carhart-Harris et al. 2012, PNAS demonstrated DMN deactivation correlates with subjective effect intensity.
Roseman, Nutt, Carhart-Harris 2018, Frontiers in Pharmacology showed that the quality of acute experience — particularly oceanic boundlessness — predicts therapeutic outcome.
MacLean, Johnson, Griffiths 2011, J Psychopharmacology validated the Mystical Experience Questionnaire and demonstrated that mystical-type experience mediates sustained increases in personality openness.

The interpretive framework: in end-of-life distress, the acute mystical-type experience — sense of unity, transcendence of time/space, sacredness — appears to facilitate existential reconciliation and meaning-making in ways conventional pharmacotherapy does not. Patients in long-term follow-up consistently rate the experience as among the most meaningful of their lives, regardless of remaining prognosis.

The Canadian regulatory context — end-of-life distress is the foundation

August 2020: the first four

Health Canada's August 4, 2020 Section 56(1) exemptions to four terminally ill Canadians for psilocybin-assisted therapy were specifically for end-of-life distress. The exemptions resulted from TheraPsil-led advocacy and represented the first legal therapeutic psilocybin access in Canada in decades. The four cases established proof-of-concept for the regulatory framework that would eventually become the SAP amendment.

March 2022: the first SAP authorization

Following the January 5, 2022 SAP amendment, the first authorization under the new framework was issued March 21, 2022 to Dr. Valorie Masuda (BC palliative-care physician) for six end-of-life patients. End-of-life distress remained the predominant approved indication in 2022–2024 SAP authorizations.

December 2022: Quebec RAMQ — the first publicly funded psychedelic therapy in Canada

Drs. Houman Farzin (palliative psychiatrist, Jewish General Hospital, McGill) and Jean-François Stephan successfully billed RAMQ for SAP-approved psilocybin-assisted therapy delivered to a Quebec patient with end-of-life distress. The June 2022 actual treatment was billed in December 2022. RAMQ subsequently modified billing codes to permit further public claims for SAP-approved Quebec patients.

This is the only established Canadian public-funding pathway for psychedelic therapy. For the cost detail, see Psilocybin-Assisted Therapy Cost in Canada.

Roots to Thrive (Nanaimo, BC) — Canada's first SAP psilocybin-assisted group therapy

Roots to Thrive — operating in partnership with Vancouver Island University and the Snuneymuxw Community Wellness Centre — received the first Health Canada SAP authorization for psilocybin-assisted group therapy targeting end-of-life patients. The program reports significant improvements in depression, PTSD, anxiety, and life functioning across early cohorts. Roots to Thrive's published clinical protocol for ketamine work appears in Frontiers in Psychiatry 2025; a parallel psilocybin-specific publication is awaited.

For the group-format detail, see Group Ketamine Therapy — the article discusses the Roots to Thrive group model that has informed the SAP psilocybin program.

End-of-life distress versus medical assistance in dying — distinct pathways

This requires honest framing because the topics co-occur in clinical conversation.

Medical Assistance in Dying (MAID) is a Canadian legal pathway under Bill C-14 (2016) and Bill C-7 (2021), with planned expansion to mental-illness-as-sole-condition delayed to March 2027. MAID is a request the patient initiates with their physician for a hastened death.

Psilocybin-assisted therapy for end-of-life distress is psychiatric and spiritual symptom support — addressing depression, anxiety, demoralization, and existential distress. It does not change underlying disease, does not affect prognosis, and is not framed as an alternative to MAID.

Some palliative-care providers, including Dr. Farzin in Quebec, have noted that psilocybin-assisted therapy can shift patients' relationship to dying — sometimes resolving suffering without changing the medical picture, sometimes clarifying the patient's values either way. But the two pathways are independent, not substitutes.

For palliative patients considering both options: psilocybin-assisted therapy and MAID are independent decisions that may or may not co-occur in any given clinical situation. Both are within the patient's autonomy and require coordination with the palliative-care team.

How does ATMA CENA support SAP-pathway palliative patients?

ATMA CENA's role for end-of-life distress patients pursuing SAP-pathway psilocybin therapy:

ATMA CENA does not initiate the SAP application. The medical SAP request is initiated by the patient's prescribing palliative-care physician or psychiatric consultant.
ATMA CENA supports preparation and integration. The ATMA CENA three-phase psychedelic-assisted therapy model adapts to psilocybin where SAP authorization is in place, with palliative-context modifications (e.g., shorter preparation phase if prognosis is limited; integration adjusted to the patient's energy level and remaining time).
The coordinated care model is particularly relevant for palliative patients: the patient's existing palliative-care team remains primary, and ATMA CENA's clinical infrastructure provides the psychotherapy wraparound specific to the dosing experience.
Coordination with palliative care: ATMA CENA's intake includes consent for release-of-information with the patient's palliative-care team, hospice if applicable, family members where appropriate, and prescribing physician.

The realistic patient pathway:

Patient or family raises psilocybin-assisted therapy with palliative-care physician or psychiatric consultant.
Physician evaluates clinical eligibility (documented psychiatric distress, conventional treatment limitations, no absolute contraindications).
If appropriate, physician initiates SAP application — TheraPsil or ATMA CENA can support the physician with template documentation.
Once SAP-authorized, ATMA CENA supports preparation, dosing-day clinical coordination, and integration in collaboration with the palliative team.
For Quebec patients, RAMQ public-funding pathway may apply via Drs. Farzin / Stephan model.

Frequently asked questions

Is psilocybin-assisted therapy a treatment for terminal cancer? No. Psilocybin-assisted therapy addresses psychiatric and existential distress in the context of terminal illness — depression, anxiety, demoralization, fear of death. It does not change the underlying disease or prognosis.

What's the strongest evidence? Griffiths 2016 (Johns Hopkins, N=51) and Ross 2016 (NYU, N=29) randomized trials in cancer-related anxiety/depression both demonstrated rapid, substantial, and sustained antidepressant and anxiolytic effects following a single high-dose psilocybin session. Agin-Liebes 2020 long-term follow-up of the Ross cohort found 60–80% maintained response at 4–5 years.

Does my hospice or palliative-care team have to be involved? Yes — coordination with the palliative-care team is essential. The SAP application is typically initiated by the patient's palliative-care physician or psychiatric consultant. ATMA CENA's intake includes release-of-information consent for coordinated care.

Is this an alternative to MAID? No. Psilocybin-assisted therapy and MAID are independent pathways. Psilocybin addresses psychiatric/existential distress without changing underlying disease; MAID is a request for hastened death. The two pathways may or may not co-occur in any given clinical situation; both are within the patient's autonomy.

How does Quebec RAMQ coverage work? Drs. Houman Farzin and Jean-François Stephan billed RAMQ for SAP-approved psilocybin-assisted therapy in December 2022. RAMQ subsequently modified billing codes for further claims. The pathway requires SAP authorization, Quebec residency, eligible indication, and Quebec-based prescribing physician.

Where can I access this in Canada? Through SAP-authorized clinicians. Specific Canadian programs with end-of-life experience include Roots to Thrive (Nanaimo BC), Quebec providers (Farzin / Stephan model and others), TheraPsil-trained clinicians across multiple provinces, and Numinus-network providers.

What if my prognosis is short? The standard three-phase model (preparation + dosing + integration) can be compressed for patients with shorter prognosis. Some Canadian palliative protocols use abbreviated preparation (1–2 sessions over 1–2 weeks) and integration adjusted to the patient's energy and remaining time.

Can I have family present? This depends on the specific clinical model and patient preference. Most published trial protocols use therapist-only support during dosing, but some palliative-care models accommodate family presence in modified roles. Discuss at intake.

What about challenging experiences during dosing? Common across all psilocybin therapy contexts; particularly meaningful in end-of-life work where grief, fear of death, and unresolved relationships often surface. The therapist team's role is non-directive presence; integration sessions translate challenging content into therapeutic insight.

Can a patient with active mania or psychosis access psilocybin therapy? No. Active psychosis, recent mania, and personal history of psychotic disorder are absolute contraindications. Patients with bipolar I or schizophrenia history should not pursue psilocybin therapy.

Does ATMA CENA deliver the dosing session itself? The dosing session is delivered under the prescribing physician's SAP authorization. ATMA CENA supports preparation and integration in coordination with the prescribing palliative or psychiatric physician via coordinated care. Specific dosing-day arrangements vary by case and clinical setting.

What does it cost? Typically CAD $2,500–$6,500 per program out-of-pocket. Filament Health often supplies SAP-approved psilocybin at no charge. Quebec RAMQ public-funding pathway applies for eligible Quebec patients. See Psilocybin-Assisted Therapy Cost in Canada.

Sources

ATMA CENA — find care near you: https://psychedelic.healthcare/find-care
Griffiths RR, et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/27909164/
Ross S, et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/27909165/
Agin-Liebes GI, et al. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/31916890/
Agrawal M, et al. (2024). Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder. Cancer. https://pubmed.ncbi.nlm.nih.gov/38105655/
Anderson BT, et al. (2020). Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men. EClinicalMedicine. https://pubmed.ncbi.nlm.nih.gov/33150319/
Carhart-Harris RL, et al. (2012). Neural correlates of the psychedelic state — DMN. PNAS. https://pubmed.ncbi.nlm.nih.gov/22308440/
Roseman L, Nutt DJ, Carhart-Harris RL (2018). Quality of acute psychedelic experience predicts therapeutic efficacy. Front Pharmacol. https://pubmed.ncbi.nlm.nih.gov/29387009/
MacLean KA, Johnson MW, Griffiths RR (2011). Mystical Experience Questionnaire validation. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/21674151/
Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
TheraPsil — Quebec first province to cover psilocybin therapy: https://therapsil.ca/quebec-first-province-to-cover-costs-of-psilocybin-assisted-psychotherapy-done-by-two-physicians/

Psilocybin Therapy for End-of-Life Distress

Psilocybin access is restricted in many places